Shukra Pharmaceuticals Limited has announced a significant strategic partnership with Wockhardt Limited, a leading global pharmaceutical company. The agreement grants Shukra Pharmaceuticals non-exclusive authorization to manage and distribute Wockhardt's products across India, marking a major milestone in Shukra's growth trajectory.

Key Highlights of the Agreement

• Scope: Shukra Pharmaceuticals will represent, distribute, and manage Wockhardt's products on a pan-India basis.
• Target Institutions: The distribution rights cover all ESIC/ESIS Hospitals and all Defence Hospitals, AFMSD, and DGAFMS units across India.
• Duration: The agreement is effective from September 9, 2025, and valid until March 2026.
• Operational Authority: Shukra is empowered to quote products, collect orders, raise invoices, and collect payments directly on behalf of Wockhardt Limited.

Product Portfolio

The distribution agreement includes high-quality, advanced anti-infective formulations from Wockhardt's portfolio, such as:

• EMROK® (Levonadifloxacin)
• MIQNAF® (Nafithromycin)

These breakthrough antibiotics are developed to combat critical infections, underlining the strategic importance of this partnership in addressing crucial healthcare needs.

Strategic Implications

This collaboration is expected to have several positive impacts on Shukra Pharmaceuticals:

1. Enhanced Market Presence: The agreement will strengthen Shukra's footprint in institutional and government healthcare networks across India.
2. Revenue Growth: The partnership is anticipated to boost Shukra's revenue visibility and operational reach.
3. Long-term Value Creation: By aligning with India's expanding healthcare and hospital infrastructure, Shukra aims to create sustained value for its shareholders.
4. Operational Expansion: The deal marks a significant expansion in Shukra's operational capabilities and market access.

Management's Perspective

The Board and Management of Shukra Pharmaceuticals express confidence that this development will have a positive and lasting impact on the company's financial and operational performance. The strategic nature of this distributorship, coupled with Wockhardt's respected position in global healthcare, underscores the significance of this agreement for Shukra Pharmaceuticals.

As the healthcare sector in India continues to grow and evolve, partnerships like these are poised to play a crucial role in improving access to advanced pharmaceutical products across the country. Investors and stakeholders will likely watch closely to see how this agreement translates into tangible growth for Shukra Pharmaceuticals in the coming quarters.

Shukra Pharmaceuticals Limited has announced a series of significant corporate actions, seeking shareholder approval through a postal ballot notice. The company is proposing a substantial increase in its authorized share capital and a generous bonus share issuance, among other resolutions.

Key Proposals

1. Capital Increase: Shukra Pharmaceuticals aims to raise its authorized share capital from Rs. 12.00 crore to Rs. 44.00 crore, a substantial increase that could pave the way for future growth initiatives.

2. Bonus Share Issuance: The company has proposed a 3:1 bonus issue, where shareholders will receive three new shares for every one share held. This move will involve capitalizing Rs. 32.84 crore from the company's securities premium and general reserves.

3. Articles of Association Amendment: To facilitate the bonus issue, Shukra Pharmaceuticals seeks to amend its Articles of Association, allowing the inclusion of general reserve and surplus accounts for bonus share purposes.

4. Managing Director's Remuneration: The company proposes to revise the monthly remuneration of Managing Director Dakshesh Shah to Rs. 8.00 lakh.

Voting Process and Timeline

Current Capital Structure

Shukra Pharmaceuticals' current paid-up capital stands at Rs. 10.95 crore, consisting of 1.09 crore equity shares with a face value of Rs. 10.00 each.

Implications for Shareholders

If approved, the bonus issue will significantly increase the number of shares held by existing shareholders without any additional cost. This move could potentially enhance liquidity in the stock and reward long-term shareholders.

The proposed capital increase and bonus issue reflect the company's confidence in its future prospects and its commitment to creating value for shareholders. However, investors should note that while bonus shares increase the number of shares held, they do not directly impact the overall value of their holdings, as the stock price typically adjusts proportionately.

Shareholders are encouraged to participate in the e-voting process to have their say in these important corporate decisions that could shape the future of Shukra Pharmaceuticals.